tetano
Editor, Senior Moderator
iScience
. 2024 Apr 10;27(5):109719.
doi: 10.1016/j.isci.2024.109719. eCollection 2024 May 17. A spike virosome vaccine induces pan-sarbecovirus antibody responses in mice
Mitch Brinkkemper[SUP] 1 2 [/SUP], Meliawati Poniman[SUP] 1 2 [/SUP], Esther Siteur-van Rijnstra[SUP] 3 [/SUP], Widad Ait Iddouch[SUP] 1 2 [/SUP], Tom P L Bijl[SUP] 1 2 [/SUP], Denise Guerra[SUP] 1 2 [/SUP], Khadija Tejjani[SUP] 1 2 [/SUP], Marloes Grobben[SUP] 1 2 [/SUP], Farien Bhoelan[SUP] 4 [/SUP], Denzel Bemelman[SUP] 4 [/SUP], Ronald Kempers[SUP] 4 [/SUP], Marit J van Gils[SUP] 1 2 [/SUP], Kwinten Sliepen[SUP] 1 2 [/SUP], Toon Stegmann[SUP] 4 [/SUP], Yme U van der Velden[SUP] 1 2 [/SUP], Rogier W Sanders[SUP] 1 2 5 [/SUP]
Affiliations
Zoonotic events by sarbecoviruses have sparked an epidemic (severe acute respiratory syndrome coronavirus [SARS-CoV]) and a pandemic (SARS-CoV-2) in the past two decades. The continued risk of spillovers from animals to humans is an ongoing threat to global health and a pan-sarbecovirus vaccine would be an important contribution to pandemic preparedness. Here, we describe multivalent virosome-based vaccines that present stabilized spike proteins from four sarbecovirus strains, one from each clade. A cocktail of four monovalent virosomes or a mosaic virosome preparation induced broad sarbecovirus binding and neutralizing antibody responses in mice. Pre-existing immunity against SARS-CoV-2 and extending the intervals between immunizations enhanced antibody responses. These results should inform the development of a pan-sarbecovirus vaccine, as part of our efforts to prepare for and/or avoid a next pandemic.
Keywords: Immunology; Virology.
. 2024 Apr 10;27(5):109719.
doi: 10.1016/j.isci.2024.109719. eCollection 2024 May 17. A spike virosome vaccine induces pan-sarbecovirus antibody responses in mice
Mitch Brinkkemper[SUP] 1 2 [/SUP], Meliawati Poniman[SUP] 1 2 [/SUP], Esther Siteur-van Rijnstra[SUP] 3 [/SUP], Widad Ait Iddouch[SUP] 1 2 [/SUP], Tom P L Bijl[SUP] 1 2 [/SUP], Denise Guerra[SUP] 1 2 [/SUP], Khadija Tejjani[SUP] 1 2 [/SUP], Marloes Grobben[SUP] 1 2 [/SUP], Farien Bhoelan[SUP] 4 [/SUP], Denzel Bemelman[SUP] 4 [/SUP], Ronald Kempers[SUP] 4 [/SUP], Marit J van Gils[SUP] 1 2 [/SUP], Kwinten Sliepen[SUP] 1 2 [/SUP], Toon Stegmann[SUP] 4 [/SUP], Yme U van der Velden[SUP] 1 2 [/SUP], Rogier W Sanders[SUP] 1 2 5 [/SUP]
Affiliations
- PMID: 38706848
- PMCID: PMC11068555
- DOI: 10.1016/j.isci.2024.109719
Zoonotic events by sarbecoviruses have sparked an epidemic (severe acute respiratory syndrome coronavirus [SARS-CoV]) and a pandemic (SARS-CoV-2) in the past two decades. The continued risk of spillovers from animals to humans is an ongoing threat to global health and a pan-sarbecovirus vaccine would be an important contribution to pandemic preparedness. Here, we describe multivalent virosome-based vaccines that present stabilized spike proteins from four sarbecovirus strains, one from each clade. A cocktail of four monovalent virosomes or a mosaic virosome preparation induced broad sarbecovirus binding and neutralizing antibody responses in mice. Pre-existing immunity against SARS-CoV-2 and extending the intervals between immunizations enhanced antibody responses. These results should inform the development of a pan-sarbecovirus vaccine, as part of our efforts to prepare for and/or avoid a next pandemic.
Keywords: Immunology; Virology.